Most cited papers from German Breast group

German Breast group

What are the most cited papers from German Breast group?

The most cited paper from German Breast group is "Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis" (Patricia Cortazar et al., 2014), with 4,858 citations. Next come "The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014" (3,221) and "Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes" (2,717).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 298 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Patricia Cortazar et al. · The Lancet Open access	13 Feb 2014	4,858
2	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Roberto Salgado et al. · Annals of Oncology Open access	11 Sep 2014	3,221
3	Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer et al. · Journal of Clinical Oncology	17 Apr 2012	2,717
4	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine Open access	5 Dec 2018	2,689
5	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Fabrice André, Eva M. Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine Open access	15 May 2019	2,660
6	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Carsten Denkert et al. · The Lancet Oncology	8 Dec 2017	2,205
7	Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer Andrew N.J. Tutt et al. · New England Journal of Medicine Open access	3 Jun 2021	1,744
8	Breast cancer Sibylle Loibl, Philip M. Poortmans, Monica Morrow et al. · The Lancet	2 Apr 2021	1,696
9	Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine Open access	Jun 2015	1,606
10	Association analysis identifies 65 new breast cancer risk loci Kyriaki Michailidou et al. · Nature Open access362 authors	20 Oct 2017	1,602
11	Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study Thorsten Kuehn, Ingo Bauerfeind, Tanja Natascha Fehm et al. · The Lancet Oncology	14 May 2013	1,498
12	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Alessandra Gennari et al. · Annals of Oncology Open access	20 Oct 2021	1,442
13	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Gϋnter von Minckwitz, Marion Jennifer Procter, Evandro de Azambuja et al. · New England Journal of Medicine Open access	5 Jun 2017	1,425
14	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Rashmi Krishna Murthy et al. · New England Journal of Medicine Open access	11 Dec 2019	1,345
15	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine Open access	20 Oct 2018	1,321
16	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Sherene Loi, Stefan Michiels, Roberto Salgado et al. · Annals of Oncology Open access	8 Mar 2014	1,286
17	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Giuseppe Curigliano et al. · Annals of Oncology Open access	11 Jun 2017	1,263
18	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Nasim Mavaddat et al. · The American Journal of Human Genetics Open access269 authors	13 Dec 2018	1,213
19	HER2-positive breast cancer Sibylle Loibl, Luca Gianni · The Lancet	6 Dec 2016	1,157
20	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey et al. · Journal of Clinical Oncology Open access	28 Jan 2021	1,053
21	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Gϋnter von Minckwitz et al. · The Lancet Oncology	30 Apr 2014	1,048
22	Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Sibylle Loibl et al. · Annals of Oncology Open access	13 Dec 2023	991
23	Molecular alterations in triple-negative breast cancer—the road to new treatment strategies Carsten Denkert, Cornelia Liedtke, Andrew N.J. Tutt et al. · The Lancet	6 Dec 2016	901
24	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial R. Jakesz, W. Jonat, Michael Gnant et al. · The Lancet	Aug 2005	881
25	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina Shona A. Hendry et al. · Advances in Anatomic Pathology Open access100 authors	2 Aug 2017	816
26	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology	28 Feb 2018	781
27	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research Shona A. Hendry et al. · Advances in Anatomic Pathology Open access100 authors	2 Aug 2017	739
28	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study S. Loibl et al. · Annals of Oncology Open access	7 May 2019	714
29	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Harold J. Burstein, Giuseppe Curigliano, Sibylle Loibl et al. · Annals of Oncology Open access	Aug 2019	695
30	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial Ben O’Leary, Rosalind J. Cutts, Yuan Liu et al. · Cancer Discovery Open access	11 Sep 2018	686
31	Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 Fabrice André, Eva Ciruelos, Dejan Juric et al. · Annals of Oncology Open access	24 Nov 2020	621
32	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Jack M. Cuzick, Ivana Šestak, John Forbes et al. · The Lancet Open access	12 Dec 2013	591
33	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Carsten Denkert et al. · The Lancet Oncology	9 Jul 2021	581
34	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) Laura Biganzoli, Hans P. M. W. Wildiers, Catherine Angela Oakman et al. · The Lancet Oncology	30 Mar 2012	575
35	Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy Nehmat Houssami, Petra Macaskill, Gϋnter von Minckwitz et al. · European Journal of Cancer ReviewOpen access	6 Jul 2012	563
36	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Nancy U. Lin et al. · Journal of Clinical Oncology Open access	29 May 2020	558
37	Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression Mika Hilvo et al. · Cancer Research	17 Mar 2011	540
38	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine	26 Jan 2012	532
39	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer Manfred Kaufmann, Gϋnter von Minckwitz, E Mamounas et al. · Annals of Surgical Oncology	22 Dec 2011	498
40	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer Nicholas C. Turner, Yuan Liu, Zhou Zhu et al. · Journal of Clinical Oncology Open access	26 Feb 2019	481
41	Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer et al. · Annals of Oncology Open access609 authors	10 Oct 2022	477
42	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer ABCTB Investigators et al. · Nature Genetics Open access476 authors	23 Oct 2017	477
43	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology	16 Jan 2012	459
44	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer Maria Vittoria Dieci et al. · Seminars in Cancer Biology Open access	12 Oct 2017	444
45	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa et al. · Journal of Clinical Oncology Open access	4 Sep 2013	431
46	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial Michael Untch et al. · The Lancet Oncology	8 Feb 2016	422
47	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Eric Hahnen et al. · JAMA Oncology Open access	17 Jul 2017	398
48	Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Marwan Kaufmann, Gϋnter von Minckwitz, Harry D. Bear et al. · Annals of Oncology Open access	13 Nov 2007	392
49	Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Robert Edward Coleman, Richard de Boer, Holger Eidtmann et al. · Annals of Oncology Open access	10 Oct 2012	341
50	The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy Lars Hanker, Sibylle Loibl, Nicole Burchardi et al. · Annals of Oncology Open access	23 Aug 2012	340

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.